Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study Investigating the Effectiveness of Pravastatin on Renal Function in Korean Dyslipidemic Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants with Type 2 diabetes (currently using an antidiabetic drug or satisfying diagnostic criteria of diabetes as defined by American Diabetes Association)~* Participants with dyslipidemia (currently using an antidyslipidemic drug or satisfying the Health Insurance Review \& Assessment Service insurance coverage treatment criteria\*) for whom drug treatment with pravastatin is confirmed~* Participants determined to be eligible as subjects at the discretion of the investigator~* Participants who voluntarily provided written consent using the Informed Consent Form on Use of Information~Exclusion Criteria:~* Participants who had administered pravastatin prior to study participation~* Participants with hypersensitivity to the investigational product or its history~* Participants with an active liver disease or persistent elevation of transaminase with an unknown cause~* Pregnant woman or women with childbearing potential, breastfeeding mothers~* Children~* Participants with severe hepatic or renal insufficiency~* Participants with myopathy~* Participants with cholestasis~* Participants with hypercholesterolemia due to hyperalphalipoproteinemia accompanied by HDL cholesterol elevation~* Participants with a genetic problem such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dyslipidemic participants with Type 2 diabetes (Type: None): Dyslipidemic participants with Type 2 diabetes who received a routine initiation dose of pravastatin 10 mg, 20 mg or 40 mg single dose once daily and maintained a low cholesterol diet throughout the study period.

Based on this trial design, predict the completion outcome and termination type (if applicable).